Skip to main content

Traps for the Unwary: The Impact of the False Claims Act on Start-Up and Venture-Stage Life Sciences Companies

A government investigation or enforcement action can disrupt a business, delay the launch of a new product, or threaten funding. Life sciences companies that participate in federal grant programs need to be aware of the risks associated with non-compliance with rules and regulations governing those programs. On November 20, 2013, Karen Lovitch, David Barmak, Kevin McGinty, and Scott Samuels of Mintz Levin will present a webinar to identify best practices for managing employees and fostering compliance in a growth company environment.

Click here to register for the webinar.

Subscribe To Viewpoints

Author

Karen S. Lovitch

Member / Chair, Health Law Practice

Karen S. Lovitch is a Mintz attorney who represents health care companies in regulatory, transactional, and operational matters. She advises them on health care regulations such as the Stark Law and the Clinical Laboratory Improvement Amendments of 1988.